Introduction
Invasive fungal infection (IFI) remains a serious complication in patients receiving antineoplastic therapy. 1, 2 Recent advances in the treatment of invasive fungal infections include broad-spectrum triazoles and ecchinocandins, a novel class of antimicrobials that inhibit fungal cell wall synthesis. 3 Caspofungin (CAP) given alone in patients with refractory aspergillosis has resulted in less than satisfactory response rates. 4, 5 Furthermore, since laboratory tests have shown a possible therapeutic advantage with combinations of CAP and other antifungal drugs, [6] [7] [8] in recent years combination antifungal therapy has been increasingly used in severely immunosuppressed cancer patients with IFI who are considered at high risk of treatment failure. [9] [10] [11] [12] In vitro antimicrobial susceptibility tests and studies of experimentally induced invasive mycosis in immunosuppressed animals indicate that CAP has a concentrationdependent fungicidal effect, 13 and dose-escalation studies in healthy volunteers have shown no evidence of increased dose-associated serious adverse events with CAP. 14, 15 However, the safety of higher doses of CAP in cancer patients and hematopoietic stem cell transplant recipients is not known. Although the efficacy of standard dose CAP (SD-CAP) in combination with other agents has been disappointing, 11, 12 the response to high-dose (HD)-CAP) in combination with other antifungal agents in patients with a high risk of treatment failure is not known. We therefore sought to evaluate the safety and efficacy of HD-CAP therapy in combination with other classes of antifungal agents for invasive fungal infections in patients receiving care at a comprehensive cancer center.
Materials and methods

Study setting, patients and design
A retrospective analysis of cancer patients with IFIs treated at The University of Texas MD Anderson Cancer Center between December 2002 and December 2004 was undertaken after obtaining Institutional Review Board approval; the requirement for patient consent was waived. Patients who had received CAP and at least one other antifungal agent were identified using a pharmacy database. A matched case-control analysis of patients who received HD-CAP (100 mg daily) and SD-CAP (70 mg followed by 50 mg daily) was performed to assess the responses to therapies and the infection-associated mortality rate. Patient and disease data were retrieved from patients' charts and computerized hospital data systems and included age, sex, race, duration of hospitalization, underlying malignancy, stem cell transplantation, graft-versushost disease, immunosuppressive therapy, systemic corticosteroid use, antineoplastic therapy, neutrophil counts 4 week before infection diagnosis, at the time antifungal therapy commenced, and during the course of antifungal therapy, complications of fungal infection, treatments for IFI, and outcome. Comorbid conditions such as diabetes, renal failure, structural lung disease including chronic obstructive pulmonary disease, hepatic dysfunction, congestive heart failure, ischemic heart disease, and APACHE II score, corticosteroid use were also recorded.
All patient samples obtained from patients in whom IFI was suspected were evaluated at MD Anderson, and fungal species were identified by standard methods. 16 
Definitions
Invasive fungal infection was defined as proven, probable, or disseminated according to the guidelines of the Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer and of the Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. 17 For probable IFIs, we considered host factors and major and minor criteria as strength of evidence for diagnosis of IFI. The demonstration of tissue-invasive mold on histological examination or the presence of fungemia in patients with clinical and radiographic evidence of deep-tissue infection was considered evidence of definite infection. Isolation of Aspergillus and Penicillium species in blood cultures alone in patients with no evidence of deep-tissue infection was regarded as pseudofungemia. 18 Isolation of Fusarium and Scedosporium species from sterile blood culture isolates obtained from separate body sites and/or more than 24 h apart even in the absence of known deep-tissue infection was also considered definite infection. [17] [18] [19] [20] Disseminated fungal infection was defined as infection involving two noncontiguous body sites; the presence of fungemia was not required to establish a diagnosis of disseminated fungal infection. [17] [18] [19] [20] Combination antifungal therapy was defined as concomitant administration of two antifungal agents given for at least 7 days and started within 24 h of each other. CAP was given as a single 70-mg dose followed by 50 mg daily (SD) or a single 100-mg dose daily (high dose). The dose of intravenous voriconazole was 6 mg/kg twice daily for two to six doses followed by 4 mg/kg twice daily, AmBisome (liposomal amphotericin B) was 5-10 mg/kg daily and intravenous itraconazole was 200 mg twice daily followed by 200 mg once daily.
Prior antifungal prophylaxis associated breakthrough IFI was defined as an infection in a patient receiving systemic antifungal prophylaxis with an agent that has known anti-mold activity such as itraconazole, voriconazole or lipid-based polyenes for a minimum of 7 days before diagnosis of the IFI. Refractory-relapsed cancer was defined as stage IV disease in patients with solid-organ malignancies, first cancer relapse following hematopoietic stem cell transplantation, or second relapse after antineoplastic therapy in patients with hematologic malignancies. Neutropenia prior to and during antifungal therapy was defined as an absolute neutrophil count lower than 500/ml. Corticosteroid use was defined as 4600 mg of prednisone or an equivalent dose of another corticosteroid given during the immediate 7 days before diagnostic samples were obtained. Acute Physiology and Chronic Health Evaluation (APACHE) II scores, which could signal the presence of multiorgan dysfunction, were calculated by standard methods. 21 For this study, we evaluated the response to antifungal therapy 4 weeks and 12 weeks after combination therapy commenced. Complete response was defined as a major improvement in symptoms and signs and radiographic findings associated with IFI, and the discontinuation of systemic antifungal therapy or the reduction of doses for secondary prophylaxis. Partial response was defined as improvement in symptoms and signs and incomplete radiographic disease resolution on X-rays or computed tomography scans, when available. Progressive disease was defined as deterioration in signs and symptoms and radiographic findings associated with IFI in patients who had received at least 7 days of systemic antifungal therapy. Stable disease was modest improvement in signs and symptoms and unchanged radiographic features associated with IFI.
Serious drug toxicity were adverse events including grade 3, 4 and grade 5 according to standard criteria described elsewhere. 22 Invasive fungal infection was considered the principal contributor to a patient's death if there was evidence of progressive fungal disease despite 7 days of combination antifungal therapy and either a post-mortem examination was consistent with organ dysfunction associated with invasive mycosis or an antemortem diagnosis of progression of fungal disease with organ failure that was known to be affected by fungal disease was established and other causes of death, such as intracranial hemorrhage, myocardial infarction, or pulmonary embolism, were not present. Sepsis, septic shock-related multiorgan failure, disseminated intravascular coagulation, and respiratory failure, including adult respiratory distress syndrome, were considered sequelae of progressive fungal infection.
Statistical analysis
Study data are presented as mean and median values7s.d. or as numbers and percentages of patients. Differences in continuous variables between the SD and HD groups were analyzed using Fisher's exact test, and differences in discrete variables between the groups were analyzed by the Wilcoxon test for unpaired samples. A backward stepwise logistic regression model was used to assess the association of discrete and continuous categorical variables with the risk of death. The variables tested in the multivariate analysis had a Po0.05 in the univariate analysis. We calculated the odds ratio (OR) for response or death from IFI and the corresponding 95% confidence interval (95% CI) for each variable. Po0.05 (2-sided) was considered indicative of statistical significance. MedCalc 7.0 computer software (MedCalc, Mariakerke, Belgium) was used for the statistical analysis.
Results
Patient and disease characteristics
Patients who had received HD-CAP had significantly more non-pulmonary fungal infections (29 vs 8% in SD group; P ¼ 0.0053) and more often had received prior antifungal therapy (71 vs 33% in SD group; P ¼ 0.0004) ( Table 1 ). In addition, significantly more patients in the HD-CAP group than in the SD group had non-Aspergillus species infection (21 vs 6%; Pp0.05). The characteristics of the fungal infections are shown in Table 2 .
The type of combination antifungal therapy in as follows: CAP plus AmBisome 44% in SD vs 41% in HD arm (P ¼ 0.766), CAP plus voriconazole 40% in SD and 44% in patients receiving HD-CAP (P ¼ 0.672). Three antifungal combinations included CAP AmBisome plus voriconazole or itraconazole in 8% of patients who had received SD vs 12% in the HD arm. Only one patient in the SD arm received a combination of CAP plus itraconazole. Six percent of patients in SD and 3% in HD arm were treated with CAP alone.
Outcomes
No serious adverse reactions were noted in patients receiving HD-CAP therapy compared to SD group (Table 3) . A single patient with refractory chronic lymphocytic leukemia and Gilbert syndrome, who had failed 3 weeks of AmBisome therapy for Aspergillus fumigatus pneumonia, developed increased serum aminotransferase after two HD-CAP combination therapy, and serum enzymes levels normalized 1 week after CAP was discontinued.
Despite the shorter duration of therapy (mean, 23720 days in HD group vs 36728 days in SD group; P ¼ 0.01), the patients who received HD-CAP had comparable response rates at 4 weeks (29 vs 22% in SD-CAP group; P ¼ 0.1) and a higher response rate 12 weeks after treatment was started (44 vs 29% in SD group; P ¼ 0.1).
The overall IFI-attributable mortality was 28 (44%) in SD group vs 9 (26%) in patients who had received HD-CAP. Interestingly, most deaths were noticed 4 weeks after treatment started; 18 of 28 (64%) in SD-CAP group, median 55794 (range, 31-381) days vs 6 of 9 (66%) in patients treated with HD-CAP, 36726 (range, 30-95) days after treatment had commenced.
Logistic regression analysis
The multivariate analysis showed no differences in response between the HD-and SD-CAP treatment groups 4 weeks after therapy started; however, at 12 weeks, there was a significantly higher probability of a favorable response in patients who had received HD-CAP (OR, 3 (Table 4) . Among the HD therapy group, all-cause mortality was not different from patients who had received SD-CAP (P ¼ 0.6; Figure 1 ). However, in Figure 2 Kaplan-Meier curves showed nonsignificant trend for IFI associated-mortality to be higher among patients in the SD arm compared with patients who were treated with HD-CAP (P ¼ 0.09).
The 
Discussion
In this study, HD-CAP was well tolerated, with a reversible transient rise in aminotransferase levels seen in a single patient with Gilbert syndrome. Patients who received antifungal therapy that included HD-CAP had a higher probability of IFI free survival 12 weeks after treatment commenced and this may in part reflect favorable response to concomitant immune enhancement therapy with granulocyte-macrophage-colony stimulating factor (GM-CSF) and interferon gamma. 23 Interestingly, there was no significant difference in patients who had received adjuvant G-CSF and/or HD donor granulocyte transfusions in either group. 24 The improved response to combination antifungal therapy occurred despite the presence of predictors of poor outcome in patients who had received HD-CAP compared to SD-CAP including non-pulmonary IFI, filamentous fungi other than Aspergillus species and significant prior exposure to systemic antifungal therapy. The difference in response was not evident 4 weeks after therapy started; only after 12 weeks of follow-up was a definite difference in treatment response observed. Neutropenia during therapy was significantly more common in patients who had received SD-CAP, although at the end therapy, neutropenia was comparable in both groups, and may have played a role in the lack of early improved response in patients receiving HD-CAP.
Although CAP has a concentration-dependent antifungal effect, a paradoxical loss of inhibition of fungal growth and reduction in killing have been noted at higher drug concentrations. 8, 25 This paradoxical effect is similar to that described for Gram-positive bacteria in response to increasing b-lactam drug concentrations (the 'Eagle effect'). 26, 27 Interestingly, this resistance to drug-induced inhibition of growth at higher concentrations of CAP High-dose caspofungin therapy A Safdar et al is reversible and is more pronounced among Candida species; 25 the echinocandin-pneumocandin-Eagle effect is less pronounced with filamentous molds, although in experimental animal models of brain zygomycosis lower CAP concentration favorable effect was reversed by increasing the concentration of the drug leading to reduced 28 This has not been noted in invasive pulmonary aspergillosis, where a modest paradoxical increase in fungal burden with increasing dose can be reversed by continued escalation of the drug concentration. 8 As clinical relevance of CAP Eagle effect was not certain, we report no increase in clinical failures associated with HD-CAP therapy, compared with SD therapy. This reversible paradoxical Eagle effect observed in experimental cases of IFI treated with increasing CAP doses perhaps is similar to the Eagle effect initially described with penicillin, 26 which is now regarded as a laboratory epiphenomenon with no detectable clinical impact.
In the past decade, a considerable shift has occurred in the fungal species causing disease in immunosuppressed patients. [29] [30] [31] Infections caused by fungi such as Aspergillus terreus, Fusarium species, Scedosporium apiospermum, Pseudallescheria boydii, Paecilomyces species, and black molds are of particular concern as these difficult-to-treat infections are often refractory to conventional amphotericin B-based antifungal therapy. [32] [33] [34] [35] Despite most of these molds being susceptible to the newer antifungals, the use of voriconazole alone is associated with a o50% response rate. 36 Therefore, combination of two and even three antifungals have been explored, 37 and appears to improve fungal clearance and infection resolution compared with experimental and clinical response to a single agent antifungal therapy. [38] [39] [40] [41] [42] The preliminary clinical experience with secondary combination antifungal therapy in patients who had failed to respond to single primary antifungal therapy has also been encouraging. 11, 12, 43 In agreement with a study by Cuenca-Estrella et al., 7 that showed indifferent antifungal effect for combinations of amphotericin B and triazoles agents, antifungal combinations with CAP, especially those with CAP plus voriconazole were associated with synergistic activity against itraconazole-resistant clinical A. fumigatus isolates. In our study, most patients in HD-and SD-arm received CAP in combination with voriconazole or AmBisome. There were no serious untoward effects in these cancer or stem cell transplant patients who were treated with either antifungal combinations or SD and HD arm of CAP therapy.
Furthermore, as the number of invasive mold infections due to non-Aspergillus species that are often amphotericin B-non-susceptible was higher in patients who had received HD-CAP therapy, an improve probability of fungal disease-free survival in these patients was reassuring. This is the first study that shows clinical experience in a large population of severely immunosuppressed patients Table 2 Characteristics of invasive fungal infections
Invasive fungal infection SD, n (%) HD, n (%) Total, n (%) High-dose caspofungin therapy A Safdar et al who had tolerated HD-CAP in combination OLAT without serious untoward effects and appears to have improved fungal disease-free survival compared with patients receiving SD-CAP combination therapy. Limitations of the study includes data were collected retrospectively, and the duration of HD-CAP therapy varied. Although shorter duration of therapy in CAP HD arm compared with SD therapy may in part be due to augmentation of CAP's concentration-dependent antifungal activity. Furthermore, over 25% of patients in the HD arm also received adjuvant immune enhancement with recombinant interferon gamma, which may have played a role in improved fungal diseasefree survival. 23 Although, most patients who had received immune enhancement therapy including G-CSF 44 and/or donor granulocyte transfusions 24 were comparable in either antifungal therapy groups. Greater than 70% of patients in the HD arm did not receive recombinant T H 1 cytokine, and logistic regression analysis did not show immune enhancement as a predictor of infection resolution or fungal disease-free survival. In summary, this study paves the way for prospective, randomized, matched trials that evaluate the potential benefit of HD-CAP combinations with or without immune enhancement therapy 45, 46 in patients with difficult-to-treat IFI. Our study abrogate concerns regarding potential toxicity of 100-mg daily CAP therapy in combination with AmBisome or voriconazole in the severely immunosuppressed Figure 2 Disease-free survival was measured from the date of CAP therapy commence to the date of death from invasive fungal infection or loss of follow-up. Survival times for patients who died from causes other than invasive fungal infection were considered censored survival times.
Median survival time was not attained in the HD-CAP group and was 16 weeks (95% CI, 8-54) in SD-CAP arm. The log-rank test of equality over strata indicated that the survival curves for the two groups do not differ significantly (P ¼ 0.0978); although, there was a non-significant trend for higher IFI associated-mortality among patients in the SD-CAP group.
patients with an underlying malignancy and hematopoietic stem cell transplantation.
